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SUSTAINED RELEASE LIPOSOMAL DRUG DELIVERY FOR TREATING OCULAR
ANGIOGENESIS
ABSTRACT:
The purpose of this experiment was to develop and evaluate a sustained release liposomal drug
delivery system for treating ocular diseases such as Diabetic Retinopathy and wet Age-related
Macular Degeneration (AMD). These diseases are characterized by ocular angiogenesis, which is
induced by the transcription factor vascular endothelial growth factor (VEGF). Anti-VEGF
antibody drugs such as Avastin and Lucentis are used to treat these ocular diseases; however, due
to their short half-life (approx. 9 days) monthly intra-vitreous injections are required which are
expensive and have low patient compliance. To improve patient care, we are developing a
surgical implant for the eye that releases anti-VEGF antibodies over an extended period. To
accomplish this, we have encapsulated these antibodies drugs within liposomes, suspending
these liposomes within a hydrogel, and injected this solution into a biodegradable polymer based
balloon implant. A SOTAX USP IV dissolution apparatus along with UV-Vis spectrophotometry
was used to measure in-vitro antibody release rates. Additionally a Fluorotron was used to
measure the drug release profiles of fluorescent tagged antibodies in-vivo for balloon implants
and direct solution injections in rabbits. These experiments are ongoing, as our goal is to reach
sustained release over a several month duration.
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INTRODUCTION:
Ocular angiogenesis is mediated through the release of the transcription factor vascular endothelial
growth factor (VEGF) from the retinal Mueller cells due to prolonged hypoxic conditions. This
transcription factor causes new blood vessels to form into the eye. These blood capillaries are
fragile and leak blood into the eye, causing blood to pool into the vitreous, resulting in permanent
loss of vision. Diabetic Retinopathy and wet Age-related Macular Degeneration (AMD) are the
main diseases characterized by ocular angiogenesis. Free extracellular VEGF results in
angiogenesis when it binds to the vascular endothelial growth factor receptor (VEGFR). These
receptors are transmembrane proteins on endothelial cells and possess a high binding affinity and
specificity for VEGF. When VEGF interacts with its complimentary VEGFR, the receptor alters
its conformation, resulting in an intracellular signaling cascade that leads to the proliferation of
endothelial cells and thus angiogenesis.
Current therapeutic intervention for these ocular diseases is conducted by administering antiVEGF antibody drugs like Avastin and Lucentis which are administered as intra-vitreous injection
into the eye. These antibody drugs have a strong binding affinity and target specificity with VEGF.
When bound to VEGF, these antibodies prevent VEGF from interacting with its receptor, thus
blocking angiogenesis from occurring. However, theses anti-VEGF drugs have relatively short
half-lifes (approx. 9 days) in the vitreous, thus administering monthly injections is a necessity for
these patients. These injections are expensive, require monthly visits, and have low patient
compliance. To improve the quality of patient care, we are developing a sustained released drug
delivery system that can be surgically implanted in the eye and which releases the anti-VEGF
antibodies over an extended period of time.
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To reach our goal, we have developed both an in vitro and in vivo drug release study. The
antibodies are encapsulated within liposomal nanoparticles and then suspended in a viscous
hydrogel, which is injected into a biodegradable polymer based balloon implant. The in vitro drug
release study is conducted using a SOTAX USP IV dissolution apparatus, which is used to simulate
the eye. The release profiles of the different formulations are determined using UV-Vis
spectrophotometry. These devices containing the formulations are circulated in 10 mM phosphate
buffer to simulate physiological pH and ocular circulation. A control with only protein is used for
comparing with the test samples. Furthermore, the antibodies are fluorescent tagged, to allow us
to specifically measure the amount of protein released over a period of time. Sample aliquots from
each formulation are taken twice a week to observe the rate of drug release. Each aliquot was
obtained via micropipette at 200 µl per sample. Each sample was then further diluted with 800 µl
of phosphate buffer to create a 1 ml solution. Solutions were homogenized and ran through UVVis spectrophotometry. Release rates of the protein antibodies were measured at 280 nm and the
fluorescent tags were measured at 494 nm. Two liters of fresh phosphate buffer was made each
month for dilutions and refilling of the SOTAX apparatus. The in vivo experiments involve
implanting Avastin liposomes embedded hydrogels filled balloon devices into the rabbits’ eyes in
order to determine the ocular pharmacokinetics. Additionally, direct injections containing the
Avastin liposome embedded hydrogel solutions and non-liposome embedded Avastin solutions
were used. The rate of drug release was measured on a weekly basis using a Fluorotron to measure
the drug release profiles. Each rabbit’s left eye was unaltered and was used as the control, while
the right eye either received an implant or a direct injection. Both eyes were measured for
comparison.
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Methods:
1.

Fluorescent tagging of protein

For easy detection of the Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA)
encapsulated within the liposomes, the proteins were labelled with fluorescein. Immunoglobulin
G was tagged using NHS fluorescein (5,6-carboxyfluorescein succinimidyl ester). The protein (1
mg/ml) was dissolved in 20 mM sodium phosphate buffer with 0.15 M NaCl at pH 8.5. 4.7 µL of
15 mmol NHS-fluorescein solution in DMSO was added to the protein solution and incubated at
room temperature for 2 hr. Unreacted NHS-fluorescein was removed by dialysis using 20 mM trisglycine buffer at pH 8. The non-reacted dye must be completely removed for optimal results and
accurate determination of the fluorophore-to-protein ratio. The absorbance of the labeled protein
at 280 nm and 488 nm was measured to calculate the protein concentration and degree of labeling.
2.

Preparation of liposomes by a modified method

Different

phospholipids

and

cholesterol

were

mixed

at

various

molar

ratios

(PC:PE:PG:Cholesterol in ratio of 60:5:5:30, 60:10:0:30, 65:5:5:25) in a round bottom flask. To
this, 10 ml of 2:1 ratio of methanol- chloroform mixture containing 1µM anti-oxidant was added
to make a uniform organic phase. The solvent was removed by rotary evaporator to get a uniform
film of lipid layer. This lipid layer was hydrated using the protein solution in a pre-determined
concentration of cryoprotectant sugar to get a final phospholipid concentration of 10 mg/ml. The
dispersion was sonicated for 5 min in a bath sonicator. The liposome solution was extruded around
10 times to obtain a uniform particle size of around 200 nm. The solution was then frozen at -70oC
for 30 min and then thawed to 40oC for 20 min. The process was repeated at least 9-10 times and
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the final sample was lyophilized after removal of excess protein using gel permeation
chromatography.
3.

Particle size measurement:

The particle size was measured by Dynamic light scattering (DLS) on a Brookhaven BI-200SM
Research Goniometer and Laser Light Scattering System (5mW He–Ne laser, λ=632 nm) using
CONTIN software. To obtain the diffusion coefficient, the intensity correlation function must be
analyzed. The hydrodynamic diameter and the particle size distribution were generated by the
software. Accuracy of the data was determined based on polydispersity and baseline difference
from the correlation curve. Particle size of the samples was measured at various stages and time
intervals as a means to determine the stability and shelf-life.
1.

Encapsulation efficiency

The change in fluorescence signal can be used to assess the membrane permeability. The extent of
the leakage from an encapsulated liposome due to contact with a certain solute was determined
from the relative fluorescence (%F) of the leaked marker (fluorescent tagged IgG) and is calculated
by equation:
Encapsulation efficiency = FT – F0
FM – F0
where, FT – Fluorescence of liposomes after incubation with solute
F0 – Initial fluorescence due to dilution in an isomolar buffer
FM – Maximal fluorescence after lysis by Triton X-100
2.

Structural stability of protein released from liposomes:
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Secondary structure analysis was performed by far UV CD using Aviv Circular Dichroism
Spectrometer, model 215 with a 50 KHz photoelastic modulator. The spectra were recorded with
0.01 cm path length quartz cuvette between 190 and 300 nm using a slit width of 1 nm and a scan
speed of 20 nm/min.
3.

Transmission electron microscopy for imaging

Briefly, a drop of a water-diluted suspension of the liposomes (about 0.05 mg/mL) was placed on
a 200-mesh formvar copper grid (Electron Microscopy Sciences), allowed to adsorb and the
surplus was removed by filter paper. A drop of 2% (w/v) aqueous solution of uranyl acetate was
added and left in contact with the sample for 5 minutes. The surplus water was removed and the
sample was dried at room temperature before the vesicles were imaged with a TEM operating at
an acceleration voltage of 200 KV.
4.

Drug release studies:

Drug release studies were performed using USP 4 dissolution apparatus (SOTAX Corporation).
The flow rate was maintained at 1 ml/min. Aliquots were removed at regular intervals and the
concentration of the drug released was screened using fluorescence spectrophotometry.
Concentration of fluorescent tagged protein released was measured using UV-Vis
spectrophotometry. The concentration of protein in the solution was measured based on the
absorbance from the fluorescent label using the equation:
Protein concentration (M) = A280 x dilution factor
Ɛprotein
where, Ɛ of IgG is ~210,000 M-1 cm-1
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5.

Animal Studies:

Two sets of Dutch belted rabbits were used as animal models for testing the liposomal
formulations. One set of rabbits received a single 0.15 ml intravitreal injection of fluorescent
tagged Bevacizumab and another set of rabbits received a 0.15 ml intravitreal injection of liposome
suspension encapsulating fluorescent tagged Bevacizumab. Both sets of rabbits had a vitrectomy
before administration of the formulations. Change in concentrations of the drug in the rabbit’s eye
will be screened non-invasively using a Fluorotron (TM) Master Ocular Fluorophotometer on a
weekly basis.
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RESULTS:
The strategy of delivering proteins to ocular compartments using carriers represents the most
promising approach to improve protein bioavailability. Lucentis and Avastin are given as monthly
injections and hence increase the risk of infection. Our current study deals with the design and
optimization of liposomes to address the problems of encapsulating proteins as well as protecting
them from degradation. Our interest in this research project was to encapsulate the protein drug in
our stable liposomal formulations, prolong the time of drug release into the eye, thereby,
decreasing the frequency as well as the cost factor for these treatments.
Fluorescein tagged Bevacizumab (Avastin) was used to study the encapsulation and drug release
of the protein. The method we used for the encapsulation of fluorescein tagged proteins was a
combination of lipid hydration, extrusion and mannitol freeze thaw methods. Particle size,
encapsulation efficiency and time of release from formulations of different concentrations of
phospholipids and cholesterol have been reported in Figure 1. TEM images of the formulations
containing conventional and stealth liposomes are displayed in Figures 2 and 4. The results from
in vitro drug release studies using conventional and stealth liposomes were performed using the
SOTAX USP 4 dissolution apparatus and the results are presented in Figures 3 and 5 respectively.
Dutch belted rabbits were used as animal models for studying the in vivo drug release kinetics.
Fluorescent tagged Avastin, in free solution and encapsulated within liposomes, was injected
intravitreally into the rabbit’s eye after vitrectomy to prevent increase in the intraocular pressure.
The release kinetics were measured on a weekly basis by scanning the rabbit’s eye using a
Fluorotron Master spectrophotometer. The Fluorotron Master is calibrated to provide readouts of
fluorescence from the fluorescent label on the Avastin. In the Fluorotron Master, a blue excitation
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light is delivered through the optics of the system to the eye and the resulting emitted fluorescent
light is collected via the same optical system. Fluorescence arbitrary units in the eye were plotted
against distance data points separated by 0.10 mm on an optical axis. This distance in millimeters
on the plot cannot be related to the actual dimensions of rabbit eye tissues. However, potential
tissue assignments to data points can be made based on comparing tissue autofluorescence peaks
and by monitoring fluorescence signal after the fluorescent marker injection in various
compartments of the eye. Figure 6 shows representative Fluorotron scans from eyes that received
a single 0.15 ml intravitreal injection of fluorescent tagged Bevacizumab. Results from this data
indicate that majority of the drug injected is eliminated within 4-5 weeks. Figure 6 shows
representative Fluorotron scans from eyes that received a single 0.15 ml intravitreal injection of
liposome suspension encapsulating fluorescent tagged Bevacizumab. Results from this data
indicate the release of Avastin into the vitreous and slow diffusion towards the back of the eye
over a period of time.
DISCUSSION:
Due to the short half-life of anti-VEGF antibody drugs within the eye, frequent injections have
become common practice. This approach is costly and time consuming, and has resulted in low
patient compliance. Additionally, such frequent injections can also lead to an increased risk of
secondary infections. By using liposomal based drug delivery systems, these problems can be
overcome through sustained release of the drugs over prolonged periods of time. This technology
possesses the potential to overcome the disadvantages of the current practices and improve
patient care as a better model for treating diseases of ocular angiogenesis.
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Figure 1: Particle size, % encapsulation and time of release from different liposomal
formulations
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Figure 2: TEM image of conventional liposomes - 60:5:5:30, 65:5:5:25 and 60:10:30 with
encapsulated Avastin
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Figure 3: Drug release profiles of conventional liposomes- 60:5:5:30, 65:10:0:25, 60:10:30 with
encapsulated Avastin
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Figure 4: TEM image of stealth liposomes 60:5:5:30, 65:5:5:25 and 60:10:30 with encapsulated
Avastin
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Figure 5: Drug release profiles of long circulating or stealth liposomes with encapsulated
fluorescein tagged Avastin

Honors Capstone
Alexander G. Thomas
Bios 499H

Figure 6: Flourotron Measurements of the In-Vivo Avastin Solution Direct Injection
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Figure 7: Flourotron Measurements of the In-Vivo Liposome Solution Direct Injection
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